Paulina Gonzalez-Latapi1, Roneil Malkani2,3. 1. Department of Neurology, Feinberg School of Medicine, Chicago, IL, USA. 2. Department of Neurology, Feinberg School of Medicine, Chicago, IL, USA. r-malkani@northwestern.edu. 3. Center for Circadian and Sleep Medicine, Northwestern University, Chicago, IL, USA. r-malkani@northwestern.edu.
Abstract
PURPOSE OF REVIEW: To provide an overview of the molecular pathways and recent genetic risk loci associated with restless legs syndrome/Willis-Ekbom disease (RLS/WED) and describe the most recent treatment guidelines. RECENT FINDINGS: Diagnostic criteria for RLS/WED now include a fifth criterion to differentiate from RLS/WED mimics. Our understanding of disease pathophysiology has improved, specifically regarding iron regulation in the brain and the role of other pathways such as opioid signaling and brain and spinal cord circuitry may play. Finally, several genetic risk loci have been described, including MEIS1 which is currently considered to be the strongest genetic risk factor for RLS/WED. Treatment guidelines now suggest α2δ ligands such as gabapentin enacarbil should be used as first-line treatment. The current literature focuses on disease pathways as well as the development of animal models based on genetic risk factors for RLS/WED. Updated treatment guidelines expand on first-line treatment options.
PURPOSE OF REVIEW: To provide an overview of the molecular pathways and recent genetic risk loci associated with restless legs syndrome/Willis-Ekbom disease (RLS/WED) and describe the most recent treatment guidelines. RECENT FINDINGS: Diagnostic criteria for RLS/WED now include a fifth criterion to differentiate from RLS/WED mimics. Our understanding of disease pathophysiology has improved, specifically regarding iron regulation in the brain and the role of other pathways such as opioid signaling and brain and spinal cord circuitry may play. Finally, several genetic risk loci have been described, including MEIS1 which is currently considered to be the strongest genetic risk factor for RLS/WED. Treatment guidelines now suggest α2δ ligands such as gabapentin enacarbil should be used as first-line treatment. The current literature focuses on disease pathways as well as the development of animal models based on genetic risk factors for RLS/WED. Updated treatment guidelines expand on first-line treatment options.
Entities:
Keywords:
Augmentation; Dopamine; Iron; Restless legs syndrome; Willis-Ekbom disease
Authors: J Winkelmann; T C Wetter; V Collado-Seidel; T Gasser; M Dichgans; A Yassouridis; C Trenkwalder Journal: Sleep Date: 2000-08-01 Impact factor: 5.849
Authors: Arthur S Walters; Cheryl LeBrocq; Anjana Dhar; Wayne Hening; Ray Rosen; Richard P Allen; Claudia Trenkwalder Journal: Sleep Med Date: 2003-03 Impact factor: 3.492
Authors: Klaus Berger; Arnold von Eckardstein; Claudia Trenkwalder; Andreas Rothdach; Ralf Junker; Stephan Karl Weiland Journal: J Neurol Date: 2002-09 Impact factor: 4.849
Authors: Maria Didriksen; Muhammad Sulaman Nawaz; Joseph Dowsett; Steven Bell; Christian Erikstrup; Ole B Pedersen; Erik Sørensen; Poul J Jennum; Kristoffer S Burgdorf; Brendan Burchell; Adam S Butterworth; Nicole Soranzo; David B Rye; Lynn Marie Trotti; Prabhjyot Saini; Lilja Stefansdottir; Sigurdur H Magnusson; Gudmar Thorleifsson; Thordur Sigmundsson; Albert P Sigurdsson; Katja Van Den Hurk; Franke Quee; Michael W T Tanck; Willem H Ouwehand; David J Roberts; Eric J Earley; Michael P Busch; Alan E Mast; Grier P Page; John Danesh; Emanuele Di Angelantonio; Hreinn Stefansson; Henrik Ullum; Kari Stefansson Journal: Commun Biol Date: 2020-11-25
Authors: Franziska C Weber; Heidi Danker-Hopfe; Ezgi Dogan-Sander; Lukas Frase; Anna Hansel; Nicole Mauche; Christian Mikutta; Diana Nemeth; Kneginja Richter; Claudia Schilling; Martina Sebestova; Marian M Spath; Christoph Nissen; Thomas C Wetter Journal: Front Psychiatry Date: 2022-03-14 Impact factor: 4.157